Effects of Digoxin on Acute, Atrial Fibrillation–Induced Changes in Atrial Refractoriness

  title={Effects of Digoxin on Acute, Atrial Fibrillation–Induced Changes in Atrial Refractoriness},
  author={Christian Sticherling and Hakan Oral and Julie Horrocks and Steven P. Chough and Robert L. Baker and Michael H. Kim and Kristina Wasmer and Frank Pelosi and Bradley P Knight and Gregory F. Michaud and S. Adam Strickberger and Fred Morady},
  journal={Circulation: Journal of the American Heart Association},
BackgroundAtrial fibrillation (AF) shortens the atrial effective refractory period (ERP) and predisposes to further episodes of AF. The acute changes in atrial refractoriness may be related to tachycardia-induced intracellular calcium overload. The purpose of this study was to determine whether digoxin, which increases intracellular calcium, potentiates the acute effects of AF on atrial refractoriness in humans. Methods and ResultsIn 38 healthy adults, atrial ERP was measured at basic drive… 

Figures and Tables from this paper

The safety of digoxin as a pharmacological treatment of atrial fibrillation
Evidence suggested that, in contrast to other antiarrhythmic drugs, digoxin is a safe drug in patients with AF, however, this safety profile can be erroneous due to the short follow-up of the studies and patient selection.
Parasympathetic Blockade Promotes Recovery from Atrial Electrical Remodeling Induced by Short‐term Rapid Atrial Pacing
Parasympathetic blockade may promote recovery from ERP shortening induced by short‐term RAP and its recovery process and the recovery time for ERP to return to pre‐RAP value was significantly shorter than during either C or P.
KB-R7943 Prevents Acute, Atrial Fibrillation–Induced Shortening of Atrial Refractoriness in Anesthetized Dogs
NCX-mediated Ca2+ influx plays an important role in acute, AF-induced AERP shortening and was maximally prolonged between 5 and 10 minutes after beginning of KB infusion and returned to baseline values within 30 minutes thereafter.
Calcium Channel Blockade for Prevention of Recurrent Atrial Fibrillation: Have We Reached a VERDICT?
  • B. Knight
  • Medicine
    Journal of cardiovascular electrophysiology
  • 2001
The hypothesis that oral verapamil prevents recurrent AF after cardioversion is tested, and the high recurrence rate of 50% within 1 month in both groups suggests that neither digoxin nor verAPamil provided a beneŽ t on the prevention of recurrent AF.
Treatment of Atrial Fibrillation and Atrial Flutter: Part II
Unless transesophageal echocardiography has shown no thrombus in the left atrial appendage before cardioversion, oral warfarin should be given for 3 weeks before elective direct current or drug cardioversion of AF and continued for at least 4 weeks after maintenance of sinus rhythm.
Atrial Fibrillation: The New Epidemic of the Ageing World.
Many cardiologists prefer, especially in elderly patients , ventricular rate control plus warfarin rather than maintaining sinus rhythm with antiarrhythmic drugs.
About Arrhythmogenic Triggers and Substrates in Aging Atria: Partners in Crime for Atrial Fibrillation Development?
In this issue of the journal, Wongcharoen and colleagues present effects of aging and ouabain on left atrial arrhythmogenicity in isolated tissue of rabbit atria, and attempt to solve parts of this puzzle that invites further discussion.
Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.
The efficacy and safety of new and investigational anti-arrhythmic agents supported by the major published randomized trials, meta-analyses and review articles are examined and a summary of guidelines recommendations are concluded.


Effect of atrial fibrillation on atrial refractoriness in humans.
In humans, several minutes of induced AF is sufficient to shorten the ERP for up to approximately 8 minutes, and the temporal recovery of the ERp is reflected in progressively shorter episodes of reinduced AF.
Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans.
Pretreatment with the calcium channel antagonist verapamil, but not the sodium channel antagonist procainamide markedly attenuates acute, AF-induced changes in atrial electrophysiological properties, and suggests that calcium loading during AF may be at least partially responsible forAF-induced electrical remodeling.
Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria.
Dioxin aggravates tachycardia-induced atrial Electrical remodeling and delays recovery from electrical remodeling in the goat, which increases the inducibility and duration of AF.
Verapamil reduces tachycardia-induced electrical remodeling of the atria.
Electrical remodeling of the atrium during rapid atrial pacing was significantly attenuated by verapamil, which suggests that electrical remodelling of theAtrial effective refractory period is triggered by the high calcium influx during rapidatrial pacing rates.
Electrophysiological Properties in Chronic Lone Atrial Fibrillation
Electrophysiological features of the atrium and sinus nodal function in chronic lone AF, which are manifestations of the abnormal atrial electrophysiology, would favor production of atrial reentry in Chronic lone AF.
Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.
Artificial maintenance of AF leads to a marked shortening of AERP, a reversion of its physiological rate adaptation, and an increase in rate, inducibility and stability of AF.
Electrical remodeling in atrial fibrillation. Time course and mechanisms.
Results of the study suggest that atrial electrical remodeling is mediated by rate-induced intracellular calcium overload, and develops quickly, is progressive, and may be persistent.
[The atrial arrhythmia syndrome of vagal origin].
The vagal effect of shortening the action potential and refractory period is recognised to be non-homogeneous in the atrial wall, and suggests a re-entry mechanism rather than hyper-excitability which would explain the usual resistance of atrial arrhythmias of vagal origin to digitalis, beta blockers and quinidine.
Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.
Digoxin reduces the frequency of symptomatic atrial fibrillation episodes, however, the estimated effect is small and may be due to a reduction in the ventricular rate or irregularity rather than an antiarrhythmic action.
Short-term effects of rapid pacing on mRNA level of voltage-dependent K(+) channels in rat atrium: electrical remodeling in paroxysmal atrial tachycardia.
Even short-term high-rate atrial excitation could differentially alter the mRNA levels of Kv1.5 gene expression, implying the possible biochemical electrical remodeling unique to paroxysmal tachycardia.